New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding
In this article:
Several blood thinners are being developed that could prevent the clots that cause heart attacks and strokes—without some of the side effects.
Advertisement
Recommended Stories
1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.
Motley Fool•FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var capsid. Beqvez is a one-time treatment designed to enable hemophilia B patients to produce FIX themselves
Benzinga•The more Americans who take Ozempic, the faster the US economy could grow, Goldman Sachs says
With the US obesity rate hovering at around 40%, tens of millions of Americans could take GLP-1 drugs over the next few years.
Business Insider•Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
Zacks•How 'Megatrends' Like Weight-Loss Drugs And Smartwatches Are Bolstering ResMed
ResMed stock jumped Friday after crushing sales estimates and wiping out worries that weight-loss drugs would squeeze sleep apnea device sales.
Investor's Business Daily•Pioneer Institute study finds IRA discourages non-opioid drug innovation
The IRA adds another hurdle to an already challenging research landscape, according to a study from the Pioneer Institute.
Pharmaceutical Technology•Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure
The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.
Investor's Business Daily•Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks
Some companies, however, reported a market capitalisation decline, including Gilead Sciences and Roche.
Pharmaceutical Technology•Bernie Sanders slams pharma giant for ‘outrageously high’ drug prices, threatening the ‘entire health care system’
Patients in the U.S. pay up to 15 times more for these drugs compared to in Canada, Europe or Japan.
Moneywise•Pfizer hemophilia gene therapy arrives in US to uncertain future
The Food and Drug Administration approval of Beqvez comes as other gene therapies for the bleeding condition struggle to gain traction.
BioPharma Dive•